Intellectual Property India Publishes Patent Application for 'Spirocyclic Dihydropyranopyrimidine Kras Inhibitors' Filed by Treeline Biosciences, Inc.

MUMBAI, India, July 5 -- Intellectual Property India has published a patent application (202517055551 A) filed by Treeline Biosciences, Inc., Watertown, U.S.A., on June 9, for 'spirocyclic dihydropyranopyrimidine kras inhibitors.'

Inventor(s) include Cabral, Shawn; Mascitti, Vincent; Decultot, Ludovic Jacky Gilbert; Herold, Jens-Martin; Hesp, Kevin D.; Lajiness, James Paul; Seim, Alexander E.; Tofoleanu, Florentina; and Tsai, Andy.

The application for the patent was published on July 4, under issue no. 27/2025.

According to the abstract released by the Intellectual Property India: "This disclosure provides compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or pharmaceutically acceptable salts thereof, that inhibit a KRas protein. These compounds are useful, for example, for treating a disease, disorder, or condition in which increased and/or sustained KRas activation (e.g., KRas activation associated with a mutant KRas protein), contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. This disclosure also provides compositions containing the compounds provided herein, or pharmaceutically acceptable salts thereof."

The patent application was internationally filed on Nov. 20, 2023, under International application No.PCT/US2023/080513.

Disclaimer: Curated by HT Syndication.